H
Hideaki Tahara
Researcher at University of Tokyo
Publications - 137
Citations - 9320
Hideaki Tahara is an academic researcher from University of Tokyo. The author has contributed to research in topics: Interleukin 12 & Immunotherapy. The author has an hindex of 48, co-authored 133 publications receiving 9012 citations. Previous affiliations of Hideaki Tahara include University of Pittsburgh.
Papers
More filters
Journal Article
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
C. L. Nastala,H. D. Edington,T. G. McKinney,Hideaki Tahara,Michael A. Nalesnik,Michael J. Brunda,Maurice K. Gately,Stanley F. Wolf,Robert D. Schreiber,Walter J. Storkus +9 more
TL;DR: IL-12 is an effective and minimally toxic antitumor agent in murine tumor models and leads to an immune-mediated rejection involving, at least in part, IFN-gamma, CD4+, and CD8+ cells.
Journal Article
Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis
Hiroshi Oka,Hitoshi Shiozaki,Kenji Kobayashi,Masatoshi Inoue,Hideaki Tahara,Tetsurou Kobayashi,Yuuichi Takatsuka,Norihisa Matsuyoshi,Shinji Hirano,Masatoshi Takeichi,Takesada Mori +10 more
TL;DR: The results suggest that the reduction of E-cad expression may play an important role in invasion and metastasis of human breast cancer.
Journal Article
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Michael B. Atkins,Michael J. Robertson,Michael S. Gordon,Michael T. Lotze,Michelle DeCoste,Jon S. Dubois,Jerome Ritz,Alan B. Sandler,Howard Edington,Pamela D. Garzone,James W. Mier,Christine Canning,Linda A. Battiato,Hideaki Tahara,Matthew L. Sherman +14 more
TL;DR: A Phase I dose escalation trial of recombinant human interleukin 12 (rhIL-12) was performed to determine its toxicity, maximum tolerated dose (MTD), pharmacokinetics, and biological and potential antineoplastic effects as discussed by the authors.
Journal Article
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
Hideaki Tahara,Herbert J. Zeh,Walter J. Storkus,Itzhak Pappo,Simon C. Watkins,Ueli Gubler,Stanley F. Wolf,Paul D. Robbins,Michael T. Lotze +8 more
TL;DR: It is suggested that local delivery of IL- 12 inhibits tumor growth in a dose dependent manner but leads to the development of an antitumor immune response when IL-12 is expressed at the tumor site at the relatively small amount indicated above.
Journal ArticleDOI
Viral vectors for gene therapy
TL;DR: Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host, and viral-mediated gene delivery has proved to be the most efficient means of gene transfer.